Abstract

Growth of the EGF receptor-expressing non-small-cell lung carcinoma cell line H125 seems to be at least partially driven by autocrine activation of the resident EGF receptors. Thus, the possibility of an EGF receptor-directed antiproliferative treatment was investigated in vitro using a monoclonal antibody (alpha EGFR ior egf/r3) against the human EGF receptor and gangliosides which are known to possess antiproliferative and anti-tyrosine kinase activity. The moderate growth-inhibitory effect of alpha EGFR ior egf/r3 was strongly potentiated by the addition of monosialoganglioside GM3. Likewise, the combination of alpha EGFR ior egf/r3 and GM3 inhibited EGF receptor autophosphorylation activity in H125 cells more strongly than either agent alone. A synergistic inhibition of EGF receptor autophosphorylation by alpha EGFR ior egf/r3 and GM3 was also observed in the human epidermoid carcinoma cell line A431. In both cell lines, the inhibition of EGF receptor autophosphorylation by GM3 was prevented by pretreatment of the cells with pervanadate, a potent inhibitor of protein tyrosine phosphatases (PTPases). Also, GM3 accelerated EGF receptor dephosphorylation in isolated A431 cell membranes. These findings indicate that GM3 has the capacity to activate EGF receptor-directed PTPase activity and suggest a novel possible mechanism for the regulation of cellular PTPases.

Highlights

  • We demonstrate a synergistic effect of xEGFR ior egf/r3 and GM3 on epidermal growth factor receptor (EGFR) signalling activity and growth in H125 human non-small-cell lung carcinoma (NSCLC) cells

  • In order to choose a suitable in vitro system for evaluation of EGFR-directed antiproliferative treatments, different lung cancer cell lines were compared for expression of EGFR using a binding assay with [1251] Epidermal growth factor (EGF)

  • Except H661 cells, all other NSCLC cell lines tested exhibited moderate to high levels of EGFR expression

Read more

Summary

Methods

Eleven different cell lines derived from human lung tumours were generously provided by Drs Gazdar (Dallas, TX, USA) and Bergh (Uppsala, Sweden). Human recombinant EGF was provided by the Center of Genetic Engineering and Biotechnology of Havana, Cuba. The monoclonal anti-EGF receptor antibody, ocEGFR ior egf/r3, was generated at the Center of Molecular Immunology of Havana as described earlier (Fernandez et al, 1992). A CD3-specific monoclonal antibody of the same isotype (IgG 2A), designated 'ior t3' was generated at the Center of Molecular Immunology of Havana. The monoclonal anti-EGF receptor antibody 425 (Rodeck et al, 1987), designated 'aEGFR mab425', was kindly provided by Dr A Luckenbach (E Merck, Darmstadt, Germany). A monoclonal antibody against the C-terminus of human EGF receptor was obtained from Zymed (South San Francisco, USA) and is designated oaEGFR-CT. The gangliosides were dissolved in phosphate-buffered saline (PBS) by sonication and passed through a 0.2-gM sterile filter

Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call